These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

34 related articles for article (PubMed ID: 22172087)

  • 1. Enhancing predictive ability of IL28B-SNPs for SVR in HCV.
    Amanzada A; Schneider S; Moriconi F; Mihm S; van Thiel DH; Ramadori G
    Aliment Pharmacol Ther; 2012 Jan; 35(2):317-8. PubMed ID: 22172087
    [No Abstract]   [Full Text] [Related]  

  • 2. IL28B rs12979860 C/T polymorphism in elderly chronic hepatitis C patients treated with pegylated-interferon and ribavirin.
    Giannini EG; Marenco S; Baldissarro I; Fazio V
    Aliment Pharmacol Ther; 2011 Aug; 34(3):398-400. PubMed ID: 21726252
    [No Abstract]   [Full Text] [Related]  

  • 3. Limitations of retrospective IL28B polymorphisms and IP-10 real life studies in hepatitis C.
    Hadziyannis SJ
    Aliment Pharmacol Ther; 2011 Jul; 34(1):102-3. PubMed ID: 21631552
    [No Abstract]   [Full Text] [Related]  

  • 4. Commentary: the ss469415590 SNP--an IL28B marker looking for a home.
    Congly SE; Lee SS
    Aliment Pharmacol Ther; 2014 Feb; 39(3):339. PubMed ID: 24397320
    [No Abstract]   [Full Text] [Related]  

  • 5. IL28B polymorphisms do not predict response to therapy in chronic hepatitis C with HCV genotype 5.
    Antaki N; Bibert S; Kebbewar K; Asaad F; Baroudi O; Alideeb S; Hadad M; Abboud D; Sabah H; Bochud PY; Negro F
    Gut; 2012 Nov; 61(11):1640-1. PubMed ID: 22345656
    [No Abstract]   [Full Text] [Related]  

  • 6. Relationship of interferon-γ-inducible protein-10 kDa with viral response in patients with various heterogeneities of hepatitis C virus genotype-4.
    Al-Ashgar HI; Khan MQ; Helmy A; Al-Thawadi S; Al-Ahdal MN; Khalaf N; Al-Qahtani A; Sanai FM
    Eur J Gastroenterol Hepatol; 2013 Apr; 25(4):404-10. PubMed ID: 23470264
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of interferon-γ-induced protein-10 serum levels with virological responses to PEG-interferon-based therapy in hepatitis C virus genotype 1 or 2 chronically infected Chinese patients.
    Wang J; Jiang D; Rao H; Yang R; Wang Y; Wei L
    Scand J Gastroenterol; 2014 Nov; 49(11):1349-58. PubMed ID: 25263691
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Boceprevir.
    Maddur H; Kwo PY
    Hepatology; 2011 Dec; 54(6):2254-7. PubMed ID: 22095684
    [No Abstract]   [Full Text] [Related]  

  • 9. Lost in translation? IL28B's discovery and the journey back to the patient.
    Clark PJ; Muir AJ
    Hepatology; 2012 Jul; 56(1):5-8. PubMed ID: 22511499
    [No Abstract]   [Full Text] [Related]  

  • 10. Association between IL28B polymorphism and treatment response in patients with genotype 4 chronic hepatitis C.
    Stättermayer AF; Hofer H; Ferenci P
    J Hepatol; 2012 Sep; 57(3):706; author reply 706-7. PubMed ID: 22748774
    [No Abstract]   [Full Text] [Related]  

  • 11. Serum inducible protein-10 chemokine as a biomarker for clearance of HCV with and without treatment in Egyptian patients.
    Tabll A; El Shenawy R; Elsharkawy H; Mohamed FZ
    Hum Antibodies; 2019; 27(4):265-273. PubMed ID: 31127759
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interferon induced protein 10 remains a useful biomarker of treatment failure in patients stratified for the interleukin-28B rs12979860 haplotype.
    Albert ML; Casrouge A; Chevaliez S; Hézode C; Rosa I; Renard P; Mallet V; Fontanet A; Pawlotsky JM; Pol S
    Hepatology; 2011 Apr; 53(4):1410-1. PubMed ID: 21480356
    [No Abstract]   [Full Text] [Related]  

  • 13. Is hepatitis C subtyping still relevant in the era of direct-acting antiviral therapy?
    Eslam M; George J
    Hepatol Int; 2015 Jan; 9(1):5-8. PubMed ID: 25788373
    [No Abstract]   [Full Text] [Related]  

  • 14. Interferon γ-induced protein 10 kinetics in treatment-naive versus treatment-experienced patients receiving interferon-free therapy for hepatitis C virus infection: implications for the innate immune response.
    Lin JC; Habersetzer F; Rodriguez-Torres M; Afdhal N; Lawitz EJ; Paulson MS; Zhu Y; Subramanian GM; McHutchison JG; Sulkowski M; Wyles DL; Schooley RT
    J Infect Dis; 2014 Dec; 210(12):1881-5. PubMed ID: 24907384
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Hepatitis C at a crossroads].
    Moradpour D; Dorta G
    Rev Med Suisse; 2010 Jan; 6(233):163-4. PubMed ID: 20214186
    [No Abstract]   [Full Text] [Related]  

  • 16. HCV infection and miravirsen.
    Janssen HL; Kauppinen S; Hodges MR
    N Engl J Med; 2013 Aug; 369(9):878. PubMed ID: 23984739
    [No Abstract]   [Full Text] [Related]  

  • 17. HCV infection and miravirsen.
    Sanchez-Niño MD; Ortiz A
    N Engl J Med; 2013 Aug; 369(9):877-8. PubMed ID: 23984740
    [No Abstract]   [Full Text] [Related]  

  • 18. [Relation of IL28B gene polymorphism to chronic hepatitis C].
    Matsuura K; Tanaka Y
    Nihon Rinsho; 2011 May; 69 Suppl 4():227-33. PubMed ID: 22096924
    [No Abstract]   [Full Text] [Related]  

  • 19. A watershed moment in the treatment of hepatitis C.
    Chung RT
    N Engl J Med; 2012 Jan; 366(3):273-5. PubMed ID: 22256811
    [No Abstract]   [Full Text] [Related]  

  • 20. Micromanaging hepatitis C virus.
    Lieberman J; Sarnow P
    N Engl J Med; 2013 May; 368(18):1741-3. PubMed ID: 23534545
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.